Efavirenz/lamivudine/tenofovir

Efavirenz/lamivudine/tenofovir
Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleoside reverse transcriptase inhibitor
Clinical data
Trade namesSymfi, Symfi Lo
Other namesEFV/3TC/TDF
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa618028
License data
Pregnancy
category
  • Contraindicated
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Symfi among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[1][2][3] It combines efavirenz, lamivudine, and tenofovir disoproxil.[3] As of 2019, it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[4] It is taken by mouth.[1][2][3]

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[3] Severe side effects may include depression, psychosis, or osteonecrosis.[3] In those with a history of epilepsy, it may increase the frequency of seizures.[3] Greater care should also be taken in those with kidney problems.[3] Its use during pregnancy appears to be unsafe.[1][2]

It is on the World Health Organization's List of Essential Medicines.[5] The combination received tentative approval in the United States in 2014,[6] and was granted approval in February 2018.[7][8] Its availability and importance is supported by Medecins Sans Frontieres.[3] It is available as a generic medication.[9][10][11]

  1. ^ a b c d "Symfi- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
  2. ^ a b c d "Symfi Lo- efavirenz, lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 25 September 2021.
  3. ^ a b c d e f g h "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO). Archived from the original on October 26, 2015.
  4. ^ World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
  5. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ^ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". U.S. Food and Drug Administration (FDA). Archived from the original on February 27, 2016. Retrieved 13 December 2017.
  7. ^ "Drug Approval Package: Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 15 August 2020.
  8. ^ "Drug Approval Package: Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 24 November 2018. Retrieved 15 August 2020.
  9. ^ "Office of Generic Drugs 2020 Annual Report". U.S. Food and Drug Administration (FDA). Retrieved 12 February 2021.
  10. ^ "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.
  11. ^ "Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 September 2021.